Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

Fletcher CH, DomBourian MG and Millward PA: Platelet transfusion for patients with cancer. Cancer Control. 22:47–51. 2015.PubMed/NCBI

Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT and Djulbegovic B: AABB Platelet Transfusion Guidelines Panel: Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 55:1116–1127. 2015. View Article : Google Scholar : PubMed/NCBI

Schrezenmeier H and Seifried E: Buffy-coat-derived pooledplatelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang. 99:1–15. 2010. View Article : Google Scholar : PubMed/NCBI

van der Meer PF: Platelet concentrates, from whole blood or collected by apheresis? Transfus Apher Sci. 48:129–131. 2013. View Article : Google Scholar : PubMed/NCBI

Holbro A, Infanti L, Sigle J and Buser A: Platelet transfusion: Basic aspects. Swiss Med Wkly. 143:w138852013.PubMed/NCBI

Novotny VM: Prevention and management of platelet transfusion refractoriness. Vox Sang. 76:1–13. 1999. View Article : Google Scholar : PubMed/NCBI

Rebulla P: Refractoriness to platelet transfusion. Curr Opin Hematol. 9:516–520. 2002. View Article : Google Scholar : PubMed/NCBI

Pavenski K, Freedman J and Semple JW: HLA alloimmunization against platelet transfusions: Pathophysiology, significance, prevention and management. Tissue Antigens. 79:237–245. 2012. View Article : Google Scholar : PubMed/NCBI

Xia WJ, Ye X, Deng J, Chen YK, Xu XZ, Ding HQ, Luo GP and Fu YS: Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients. Zhonghua Xue Ye Xue Za Zhi. 31:594–598. 2010.(In Chinese). PubMed/NCBI

Eisenberg S: Refractory response to platelet transfusion therapy. J Infus Nurs. 33:89–97. 2010. View Article : Google Scholar : PubMed/NCBI

Hod E and Schwartz J: Platelet transfusion refractoriness. Br J Haematol. 142:348–360. 2008. View Article : Google Scholar : PubMed/NCBI

Shastry S and Chaudhary R: Clinical factors influencing corrected count increment. Transfus Apheresis Sci. 47:327–330. 2012. View Article : Google Scholar

Böck M, Rahrig S, Kunz D, Lutze G and Heim MU: Platelet concentrates derived from buffy coat and apheresis: Biochemical and functional differences. Transfus Med. 12:317–324. 2002. View Article : Google Scholar : PubMed/NCBI

Zebrowska A, Lipska A, Rogowska A, Bujno M, Nedzi M and Radziwon P: Quality of buffy-coat-derived platelet concentrates prepared using automated system terumo automated centrifuge and separator integration (TACSI). Pol Merkur Lekarski. 30:191–194. 2011.(In Polish). PubMed/NCBI

Yang M, Luo H, Shu B, An BQ, Xia SQ and Wang ML: Analysis on effectiveness of platelet transfusion in 1786 patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:1038–1041. 2013.(In Chinese). PubMed/NCBI

Kirkley SA and Blumberg N: Use of single donor platelets. Blood Rev. 8:142–147. 1994. View Article : Google Scholar : PubMed/NCBI

Cid J, Ramiro L, Escoda L and Llorente A: Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval. Vox Sang. 96:29–33. 2009. View Article : Google Scholar : PubMed/NCBI

Feng ML, Liu DZ, Shen W, Wang JL, Guo ZH, Zhang X, Du KM, Qian KC and Zhao TM: Establishment of an HPA-1- to −16-typed platelet donor registry in China. Transfus Med. 16:369–374. 2006. View Article : Google Scholar : PubMed/NCBI

Yuan Q, Chen X, Cheng L, Zhou CH, Fu XM, Li YP, Wang NH and Wang L: Prevention of platelet transfusion refractoriness and HLA alloimmunization by leukocyte filtered platelet transfusion: A meta analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 33:412–420. 2011.(In Chinese). PubMed/NCBI